Melipramin (Imipramine Hydrochloride)

Imipramine Hydrochloride, a tricyclic antidepressant, is used to treat several psychiatric and urological conditions.

• Major depressive disorder: alleviates depressive symptoms and improves overall mood.
• Panic disorder: reduces the frequency and severity of panic attacks.
• Nocturnal enuresis: decreases nighttime urinary episodes in children and adolescents.

• Imipramine Hydrochloride inhibits the reuptake of norepinephrine and serotonin at neuronal synapses, increasing their extracellular concentrations. The enhanced neurotransmitter activity restores the balance of mood-regulating pathways in the central nervous system, leading to antidepressant and anxiolytic effects.

Imipramine Hydrochloride may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Dry mouth: reduced salivary secretion causing discomfort.
• Constipation: slowed gastrointestinal motility.
• Drowsiness: increased sedation, especially at treatment initiation.
• Blurred vision: temporary visual disturbances.
• Weight gain: modest increase in body weight over time.
• Orthostatic hypotension: dizziness upon standing.

Serious or Rare Side Effects

• Cardiac arrhythmia: irregular heart rhythm that may be life‑threatening.
• Seizures: risk of convulsive episodes, particularly in predisposed individuals.
• Severe hypotension: marked drop in blood pressure leading to fainting.
• Hepatic toxicity: abnormal liver function tests or hepatitis.
• Agranulocytosis: dangerously low white‑blood‑cell count.
• Suicidal thoughts: emergence or worsening of suicidal ideation.

Before prescribing Imipramine Hydrochloride, clinicians should consider several safety measures.

• Assess cardiac history: obtain a baseline ECG and monitor for conduction abnormalities.
• Monitor for suicidal ideation: especially during the first few weeks of therapy.
• Avoid abrupt discontinuation: taper the dose under medical supervision to prevent withdrawal.
• Use caution in elderly patients: increased risk of confusion, falls, and anticholinergic effects.
• Avoid concomitant MAO inhibitors: ensure a washout period of at least 14 days.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Imipramine Hydrochloride can interact with several medicines, requiring careful management.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome; maintain a minimum 14‑day washout.
• Selective serotonin reuptake inhibitors (SSRIs) or other serotonergic agents: may precipitate serotonin syndrome.
• Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increase imipramine plasma levels and toxicity.

Moderate Interactions (Monitor Closely)

• Antihypertensive drugs: additive hypotensive effect, monitor blood pressure.
• Central nervous system depressants (e.g., benzodiazepines, alcohol): enhanced sedation and respiratory depression.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): increased risk of gastrointestinal bleeding.